Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT009
MIFTS: 67

Diabetes Mellitus

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetes Mellitus

About this section

MalaCards integrated aliases for Diabetes Mellitus:

Name: Diabetes Mellitus 12 73 29 54 6 44 15 17 70 32
Diabetes 6 42 3 15 39 70

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases Rare diseases
Anatomical: Endocrine diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9351
ICD9CM 34 250
MeSH 44 D003920
NCIt 50 C2985
SNOMED-CT 67 267467004
UMLS 70 C0011847 C0011849
Sources

Summaries for Diabetes Mellitus

About this section
MedlinePlus : 42 Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes. Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes. Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, also known as diabetes, is related to type 2 diabetes mellitus and type 1 diabetes mellitus, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus is KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11), and among its related pathways/superpathways are MicroRNAs in cancer and Regulation of beta-cell development. The drugs Curcumin and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, pancreas and bone.

Disease Ontology : 12 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

CDC : 3 Diabetes is a chronic (long-lasting) disease that affects how your body turns food into energy. There are three main types of diabetes: type 1, type 2, and gestational diabetes (diabetes while pregnant).

Novus Biologicals : 55 Diabetes is a disease in which the body does not produce or properly use insulin. There are four major types of diabetes: Type 1, Type 2, Gestational and Pre-Diabetes. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disease resulting when one's own immune system destroys insulin-producing beta cells in the pancreas. This causes the pancreas to produce little or no insulin. In type 2 diabetes, the body either does not produce enough insulin or beta cells ignore insulin. Gestational diabetes refers to high glucose levels caused by pregnancy. Pre-diabetes is a condition in which blood glucose levels are high, but not high enough for the diagnosis of type 2 diabetes.

Wikipedia : 73 Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by a... more...

Sources

Related Diseases for Diabetes Mellitus

About this section

Diseases in the Diabetes Mellitus family:

Type 1 Diabetes Mellitus 2 Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus 3
Type 1 Diabetes Mellitus 4 Type 1 Diabetes Mellitus 5
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 11 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 12 Type 2 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 17
Type 2 Diabetes Mellitus 3 Diabetes Mellitus, Congenital Autoimmune
Type 1 Diabetes Mellitus 18 Type 2 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 19 Type 1 Diabetes Mellitus 20
Type 1 Diabetes Mellitus 21 Type 1 Diabetes Mellitus 22
Type 1 Diabetes Mellitus 23 Type 1 Diabetes Mellitus 24
Type 2 Diabetes 5 Rare Diabetes Mellitus Type 1
Rare Diabetes Mellitus Type 2 Rare Diabetes Mellitus

Diseases related to Diabetes Mellitus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3272)
# Related Disease Score Top Affiliating Genes
1 type 2 diabetes mellitus 34.7 WFS1 SPINK1 MIR17 KCNJ11 HNF1A GCK
2 type 1 diabetes mellitus 34.5 WFS1 MEG3 HNF1A GCK
3 permanent neonatal diabetes mellitus 34.3 WFS1 RFX6 KCNJ11 HNF1A GCK
4 maturity-onset diabetes of the young 34.0 WFS1 RFX6 KCNJ11 HNF1A GCK
5 neonatal diabetes 34.0 RFX6 KCNJ11 GCK
6 gestational diabetes 33.9 KCNJ11 HNF1A GCK
7 transient neonatal diabetes mellitus 33.9 RFX6 KCNJ11 GCK
8 wolfram syndrome 33.8 WFS1 KCNJ11 GCK
9 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 33.8 WFS1 RFX6 KCNJ11
10 maturity-onset diabetes of the young, type 1 33.5 KCNJ11 HNF1A GCK
11 maturity-onset diabetes of the young, type 2 33.4 WFS1 KCNJ11 HNF1A GCK
12 type 1 diabetes mellitus 11 33.3 HNF1A CELA2A
13 maturity-onset diabetes of the young, type 3 33.0 KCNJ11 HNF1A GCK
14 maturity-onset diabetes of the young, type 4 33.0 KCNJ11 HNF1A GCK
15 maturity-onset diabetes of the young, type 6 32.9 KCNJ11 HNF1A GCK
16 pancreatic agenesis 32.8 RFX6 KCNJ11 GCK
17 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 32.7 KCNJ11 GCK
18 maturity-onset diabetes of the young, type 7 32.7 KCNJ11 GCK
19 maturity-onset diabetes of the young, type 10 32.6 KCNJ11 GCK
20 maturity-onset diabetes of the young, type 9 32.6 KCNJ11 GCK
21 insulinoma 32.4 WFS1 MEN1 HNF1A GCK
22 pancreatitis, hereditary 32.3 SPINK1 MIR99A MIR197
23 body mass index quantitative trait locus 11 32.3 MIR30E MIR17 MIR155 MIR140 KCNJ11 HNF1A
24 monogenic diabetes 32.1 KCNJ11 HNF1A GCK
25 hyperinsulinemic hypoglycemia 31.8 MEN1 KCNJ11 HNF1A GCK
26 lipoprotein quantitative trait locus 31.8 MIR17 MIR155 MIR145 MIR140 CELA2A CDKN2B-AS1
27 arteries, anomalies of 31.6 MIR30E MIR17 MIR155 MIR145 MIR140 MIR132
28 hypertension, essential 31.4 MIR30E MIR17 MIR155 MIR145 MEN1 CELA2A
29 glucose metabolism disease 31.4 MIR17 MIR155 MIR140 KCNJ11 GCK
30 renal cysts and diabetes syndrome 31.3 KCNJ11 HNF1A GCK
31 bile duct disease 31.3 MIR30E MIR17 MIR145 MIR140
32 cardiovascular system disease 31.3 MIR17 MIR155 MIR145 CDKN2B-AS1
33 stomach disease 31.2 MIR17 MIR155 MIR145 MIR140
34 pancreatic cancer 31.1 SPINK1 MIR99A MIR375 MIR17 MIR155 MIR145
35 factitious disorder 31.1 KCNJ11 GCK
36 prostate disease 31.1 MIR99A MIR30E MIR17 MIR145 MIR140 MEG3
37 maturity-onset diabetes of the young, type 13 31.0 KCNJ11 GCK
38 pituitary adenoma 30.9 MIR197 MIR132 MEN1 MEG3
39 rectum cancer 30.9 MIR99A MIR17 MIR145
40 colonic disease 30.8 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
41 pancreas, annular 30.8 SPINK1 RFX6
42 munchausen by proxy 30.7 KCNJ11 GCK
43 cervical cancer 30.7 MIR17 MIR155 MIR145 MEG3 CDKN2B-AS1
44 intestinal atresia 30.7 RFX6 MEG3 GCK
45 glioma 30.6 MIR17 MIR140 MEG3 CDKN2B-AS1
46 hepatocellular carcinoma 30.6 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
47 renal cell carcinoma, nonpapillary 30.6 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
48 esophageal cancer 30.5 MIR375 MIR30E MIR145 MIR140 MEG3 CDKN2B-AS1
49 maternal uniparental disomy 30.5 WFS1 MEG3
50 myeloma, multiple 30.5 MIR17 MIR145 MIR140 MEG3

Graphical network of the top 20 diseases related to Diabetes Mellitus:



Diseases related to Diabetes Mellitus
Sources

Symptoms & Phenotypes for Diabetes Mellitus

About this section

UMLS symptoms related to Diabetes Mellitus:


tremor; angina pectoris; equilibration disorder; symptoms
Sources

Drugs & Therapeutics for Diabetes Mellitus

About this section

Drugs for Diabetes Mellitus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 953)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
2
Thrombin Approved, Investigational Phase 4
3
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
4
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
5
Petrolatum Approved, Investigational Phase 4 8009-03-8
6
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
9
Vorapaxar Approved Phase 4 618385-01-6
10
Empagliflozin Approved Phase 4 864070-44-0
11
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
12
Ethanol Approved Phase 4 64-17-5 702
13
Sertraline Approved Phase 4 79617-96-2 68617
14
Fenofibrate Approved Phase 4 49562-28-9 3339
15
Azilsartan medoxomil Approved, Investigational Phase 4 863031-21-4
16
Tocopherol Approved, Investigational Phase 4 1406-66-2
17
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
21
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
24
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
25
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
26
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
27
carbamide peroxide Approved Phase 4 124-43-6
28
Indapamide Approved Phase 4 26807-65-8 3702
29
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
30
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
31
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
32
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
33
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
34
Sodium citrate Approved, Investigational Phase 4 68-04-2
35
Chlorzoxazone Approved Phase 4 95-25-0 2733
36
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
37
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
38
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
39
Ziprasidone Approved Phase 4 146939-27-7 60854
40
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
41
Trandolapril Approved Phase 4 87679-37-6 5484727
42
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
43
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
44
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
45
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
46
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
47
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
48
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
49
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
50
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
2 The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
3 Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial) Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
4 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
5 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
6 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
7 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
8 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
9 A Pilot Study to Determine the Impact of Real-Time Continuous Glucose Monitoring (CGM) on Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
10 Efficacy and Safety of Empagliflozin Compared With Linagliptin in New-onset Diabetes Mellitus After Kidney Transplantation Unknown status NCT03642184 Phase 4 Empagliflozin;Linagliptin
11 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
12 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics. Unknown status NCT01418456 Phase 4 antibiotics
15 Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women Unknown status NCT01511835 Phase 4 Folic Acid
16 Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
17 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
18 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
19 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
20 The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients Unknown status NCT03458715 Phase 4 SGLT2 inhibitor (Empagliflozin 25 MG);DPP4 inhibitor (Linagliptin 5 MG)
21 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
22 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
23 The Effects of Empagliflozin on Functional and Structural Arterial Wall Characteristics Unknown status NCT03639545 Phase 4 Empagliflozin 25mg;Metformin;Empagliflozin/Metformin;Placebos
24 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
25 A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus. Unknown status NCT00182494 Phase 4
26 Effect of Metformin as add-on Therapy on Glycemic Control and Other Diabetes-Related Outcomes in Type 1 Diabetic Patients:a Open-label,Self-control Study Unknown status NCT03590262 Phase 4 Metformin
27 GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes Unknown status NCT03029351 Phase 4 Exenatide Extended Release for Inj Susp 2 MG;Placebos
28 To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
29 A-One: A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone Unknown status NCT03313960 Phase 4 Afrezza plus One Drop | Premium
30 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
31 Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation. Unknown status NCT00430040 Phase 4 carvedilol;lisinopril
32 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
33 Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose? Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
34 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
35 Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes Unknown status NCT01240070 Phase 4
36 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
37 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
38 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus Unknown status NCT03120299 Phase 4 Omega-3 fatty acid;Placebos
39 The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
40 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
41 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
42 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
43 Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes Unknown status NCT03887416 Phase 4 Dapagliflozin 10 MG Oral Tablet [Farxiga];Placebo Oral Tablet
44 A 12-week Study to Compare the Effects of Vildagliptin Versus Glibenclamide on Glycemic Variability After a Sub Maximal Exercise Test in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Unknown status NCT01867502 Phase 4 MET + Vildagliptin Group;MET + Glibenclamide Group
45 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
46 A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
47 The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Unknown status NCT02372630 Phase 4 Linagliptin;Placebo
48 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (Short Title: TITRATE) Unknown status NCT02361489 Phase 4
49 The Effect of n-3 Fatty Acid Supplementation on the Expression of Sirt-1, Adiponectin Receptor 1 (AdipoR1) & Adiponectin Receptor 2 (AdipoR2) Genes of PBMC and Circulatory Levels of Resistin,Monocyte Chemotactic Protein (MCP-1) and Adiponectin of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
50 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin

Search NIH Clinical Center for Diabetes Mellitus

Inferred drug relations via UMLS 70 / NDF-RT 51 :


CHROMIUM PICOLINATE

Cochrane evidence based reviews: diabetes mellitus

Sources

Genetic Tests for Diabetes Mellitus

About this section

Genetic tests related to Diabetes Mellitus:

# Genetic test Affiliating Genes
1 Diabetes Mellitus 29
Sources

Anatomical Context for Diabetes Mellitus

About this section

MalaCards organs/tissues related to Diabetes Mellitus:

40
Endothelial, Pancreas, Bone, Liver, Bone Marrow, Heart, Skeletal Muscle
Sources

Publications for Diabetes Mellitus

About this section

Articles related to Diabetes Mellitus:

(show top 50) (show all 54766)
# Title Authors PMID Year
1
Associations of maternal diabetes mellitus and adiponectin gene polymorphisms with congenital heart disease in offspring: A case-control study. 42 61
33655931 2021
2
Metformin use in cancer survivors with diabetes reduces all-cause mortality, based on the Korean National Health Insurance Service between 2002 and 2015. 42 61
33725979 2021
3
Acupuncture for chronic constipation in patients with diabetes mellitus: A protocol for systematic review. 42 61
33655948 2021
4
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
5
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. 6
31358993 2019
6
HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. 61 54
19252740 2009
7
MicroRNA expression in human omental and subcutaneous adipose tissue. 47
19259271 2009
8
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. 54 61
18060660 2008
9
Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. 54 61
17630927 2007
10
[The role of insulin resistance and resistin in pathogenesis of diabetes mellitus with special attention to diabetes in pregnancy]. 61 54
16363386 2005
11
Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. 54 61
15781031 2005
12
PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. 54 61
15654230 2005
13
A pancreatic islet-specific microRNA regulates insulin secretion. 47
15538371 2004
14
Diabetes mellitus in adults: association of HLA DRB1 and DQB1 diabetes risk alleles with GADab presence and C-peptide secretion. 54 61
15388265 2004
15
Diabetes mellitus in Tropical Chronic Pancreatitis Is Not Just a Secondary Type of Diabetes. 61 54
15258409 2004
16
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. 61 54
12867534 2003
17
Analysis of a non-functional HNF-1alpha (TCF1) mutation in Japanese subjects with familial type 1 diabetes. 54 61
11668618 2001
18
The length of the CTLA-4 microsatellite (AT)N-repeat affects the risk for type 1 diabetes. Diabetes Incidence in Sweden Study Group. 61 54
11092697 2000
19
Molecular genetics of diabetes mellitus in Chinese subjects: identification of mutations in glucokinase and hepatocyte nuclear factor-1alpha genes in patients with early-onset type 2 diabetes mellitus/MODY. 54 61
10588527 1999
20
Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. 54 61
9817917 1998
21
Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule. 54 61
9498628 1998
22
A case of type-1 diabetes mellitus formerly diagnosed as maturity-onset diabetes of the young (MODY) carrying suggestive MODY3 gene. 54 61
9483378 1997
23
The beta cell glucokinase promoter variant is an unlikely risk factor for diabetes mellitus. Diabetes Incidence Study in Sweden (DISS). 54 61
9267992 1997
24
Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. 61 54
9169397 1997
25
Evaluation of TAP1 polymorphisms with insulin dependent diabetes mellitus in Finnish diabetic patients. The Childhood Diabetes in Finland (DiMe) Study Group. 61 54
9129974 1997
26
Deletion of Gly723 in the insulin receptor substrate-1 of a patient with noninsulin-dependent diabetes mellitus. 61 54
8723689 1996
27
Dramatic increase in incidence of insulin dependent diabetes mellitus in Western Australia. 54 61
7935096 1994
28
Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. 61
33685340 2021
29
Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. 61
33345632 2021
30
Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. 61
33403891 2021
31
Inhibitory evaluation of Curculigo latifolia on α-glucosidase, DPP (IV) and in vitro studies in antidiabetic with molecular docking relevance to type 2 diabetes mellitus. 61
33249946 2021
32
Data-driven policies needed to turn the tide on diabetes. 61
33189185 2021
33
Rury Holman: the science of diabetes and a life of trials. 61
33189183 2021
34
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. 61
33189186 2021
35
Effect of leech-centipede medicine on improving erectile function in diabetes-induced erectile dysfunction rats via PDE5 signalling pathway-related molecules. 61
33569974 2021
36
Effect of Lupinus rotundiflorus gamma conglutin treatment on JNK1 gene expression and protein activation in a rat model of type 2 diabetes. 61
33784492 2021
37
Diabetes in the Hospital—A Nationwide Analysis of all Hospitalized Cases in Germany With and Without Diabetes, 2015-2017. 61
33678220 2021
38
New insight in molecular mechanisms regulating SIRT6 expression in diabetes: Hyperglycaemia effects on SIRT6 DNA methylation. 61
33251641 2021
39
Antioxidant Sirt1/Akt axis expression in resveratrol pretreated adipose-derived stem cells increases regenerative capability in a rat model with cardiomyopathy induced by diabetes mellitus. 61
33421145 2021
40
Microfluidic-based synthesized carboxymethyl chitosan nanoparticles containing metformin for diabetes therapy: In vitro and in vivo assessments. 61
33766375 2021
41
Current concepts and challenges in managing ankle fractures in the presence of diabetes: A systematic review of the literature. 61
33717970 2021
42
Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence—Incidence and Risk Factors. 61
33632388 2021
43
Per- and polyfluoroalkyl substances and calcifications of the coronary and aortic arteries in adults with prediabetes: Results from the diabetes prevention program outcomes study. 61
33631604 2021
44
Role of the DNAJ/HSP40 family in the pathogenesis of insulin resistance and type 2 diabetes. 61
33676026 2021
45
Defining the underlying defect in insulin action in type 2 diabetes. 61
33730188 2021
46
Alleviation of diabetes mellitus through the restoration of β-cell function and lipid metabolism by Aloe vera (L.) Burm. f. extract in obesogenic WNIN/GR-Ob rats. 61
33588009 2021
47
Impact of Telehealth Interventions on Medication Adherence for Patients With Type 2 Diabetes, Hypertension, and/or Dyslipidemia: A Systematic Review. 61
32815400 2021
48
Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. 61
33491105 2021
49
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors? 61
33626385 2021
50
Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. 61
33621623 2021
Sources

Variations for Diabetes Mellitus

About this section

ClinVar genetic disease variations for Diabetes Mellitus:

6 (show all 41)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HNF1A NM_000545.8(HNF1A):c.1139del (p.Val380fs) Deletion Pathogenic 916726 GRCh37: 12:121434375-121434375
GRCh38: 12:120996572-120996572
2 HNF1A NM_000545.8(HNF1A):c.1310-1G>A SNV Pathogenic 916727 GRCh37: 12:121435276-121435276
GRCh38: 12:120997473-120997473
3 WFS1 NM_001145853.1(WFS1):c.2015T>C SNV Pathogenic 918069 GRCh37:
GRCh38:
4 RFX6 NM_173560.4(RFX6):c.224-12A>G SNV Pathogenic 497 rs587776515 GRCh37: 6:117198947-117198947
GRCh38: 6:116877784-116877784
5 GCK NM_000162.5(GCK):c.772G>A (p.Gly258Ser) SNV Pathogenic 918070 GRCh37: 7:44187340-44187340
GRCh38: 7:44147741-44147741
6 KCNJ11 NM_000525.3(KCNJ11):c.601C>T (p.Arg201Cys) SNV Pathogenic 8668 rs80356625 GRCh37: 11:17409038-17409038
GRCh38: 11:17387491-17387491
7 KCNJ11 NM_000525.3(KCNJ11):c.685G>A (p.Glu229Lys) SNV Pathogenic 158683 rs587783673 GRCh37: 11:17408954-17408954
GRCh38: 11:17387407-17387407
8 KCNJ11 NM_000525.3(KCNJ11):c.964G>A (p.Glu322Lys) SNV Pathogenic 21203 rs193929355 GRCh37: 11:17408675-17408675
GRCh38: 11:17387128-17387128
9 KCNJ11 NM_000525.3(KCNJ11):c.988T>C (p.Tyr330His) SNV Pathogenic 158688 rs587783675 GRCh37: 11:17408651-17408651
GRCh38: 11:17387104-17387104
10 MEN1 NM_000244.3(MEN1):c.669+1del Deletion Pathogenic 374107 rs1057518903 GRCh37: 11:64575362-64575362
GRCh38: 11:64807890-64807890
11 HNF1A NM_000545.6(HNF1A):c.812G>A (p.Arg271Gln) SNV Pathogenic 449403 rs779184183 GRCh37: 12:121432065-121432065
GRCh38: 12:120994262-120994262
12 HNF1A NM_000545.6(HNF1A):c.599G>A (p.Arg200Gln) SNV Pathogenic 381588 rs893256143 GRCh37: 12:121431395-121431395
GRCh38: 12:120993592-120993592
13 WFS1 NM_006005.3(WFS1):c.1362_1377del (p.Pro453_Tyr454insTer) Deletion Pathogenic 916728 GRCh37: 4:6302884-6302899
GRCh38: 4:6301157-6301172
14 WFS1 NM_006005.3(WFS1):c.1514G>A (p.Cys505Tyr) SNV Pathogenic 918063 GRCh37: 4:6303036-6303036
GRCh38: 4:6301309-6301309
15 WFS1 NM_006005.3(WFS1):c.817G>T (p.Glu273Ter) SNV Pathogenic 918066 GRCh37: 4:6296872-6296872
GRCh38: 4:6295145-6295145
16 WFS1 NM_006005.3(WFS1):c.1839G>A (p.Trp613Ter) SNV Pathogenic 349320 rs143064649 GRCh37: 4:6303361-6303361
GRCh38: 4:6301634-6301634
17 WFS1 NM_006005.3(WFS1):c.1672C>T (p.Arg558Cys) SNV Pathogenic 198835 rs199946797 GRCh37: 4:6303194-6303194
GRCh38: 4:6301467-6301467
18 SPINK1 NM_003122.4(SPINK1):c.194+2T>C SNV Pathogenic 132142 rs148954387 GRCh37: 5:147207583-147207583
GRCh38: 5:147828020-147828020
19 WFS1 NM_006005.3(WFS1):c.2020G>A (p.Gly674Arg) SNV Pathogenic 215394 rs200672755 GRCh37: 4:6303542-6303542
GRCh38: 4:6301815-6301815
20 KCNJ11 NM_000525.3(KCNJ11):c.679G>A (p.Glu227Lys) SNV Pathogenic 158682 rs587783672 GRCh37: 11:17408960-17408960
GRCh38: 11:17387413-17387413
21 CELA2A NM_033440.3(CELA2A):c.209C>T (p.Thr70Met) SNV Pathogenic 633595 rs372947070 GRCh37: 1:15788135-15788135
GRCh38: 1:15461640-15461640
22 CELA2A NM_033440.3(CELA2A):c.639+1G>C SNV Pathogenic 633594 rs752331004 GRCh37: 1:15792640-15792640
GRCh38: 1:15466145-15466145
23 CELA2A NM_033440.3(CELA2A):c.253C>A (p.Leu85Met) SNV Pathogenic 633593 rs558493952 GRCh37: 1:15789253-15789253
GRCh38: 1:15462758-15462758
24 CELA2A NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn) SNV Pathogenic 633592 rs1352544800 GRCh37: 1:15789885-15789885
GRCh38: 1:15463390-15463390
25 HNF1A NM_000545.8(HNF1A):c.824A>T (p.Glu275Val) SNV Pathogenic 918065 GRCh37: 12:121432077-121432077
GRCh38: 12:120994274-120994274
26 HNF1A NM_000545.8(HNF1A):c.639C>G (p.Ile213Met) SNV Likely pathogenic 918062 GRCh37: 12:121431435-121431435
GRCh38: 12:120993632-120993632
27 HNF1A NM_000545.8(HNF1A):c.404A>C (p.Asp135Ala) SNV Likely pathogenic 918061 GRCh37: 12:121426713-121426713
GRCh38: 12:120988910-120988910
28 INS-IGF2 , INS NM_000207.3(INS):c.286T>C (p.Cys96Arg) SNV Likely pathogenic 918067 GRCh37: 11:2181129-2181129
GRCh38: 11:2159899-2159899
29 PMM2 NM_000303.3(PMM2):c.422G>A (p.Arg141His) SNV Likely pathogenic 7706 rs28936415 GRCh37: 16:8905010-8905010
GRCh38: 16:8811153-8811153
30 KCNJ11 NM_000525.3(KCNJ11):c.498C>G (p.Cys166Trp) SNV Likely pathogenic 158676 rs587783669 GRCh37: 11:17409141-17409141
GRCh38: 11:17387594-17387594
31 HNF1A NM_000545.6(HNF1A):c.475C>T (p.Arg159Trp) SNV Likely pathogenic 429750 rs765432081 GRCh37: 12:121426784-121426784
GRCh38: 12:120988981-120988981
32 WFS1 NM_006005.3(WFS1):c.961A>C (p.Thr321Pro) SNV Likely pathogenic 918064 GRCh37: 4:6302483-6302483
GRCh38: 4:6300756-6300756
33 PMM2 NM_000303.3(PMM2):c.584A>G (p.His195Arg) SNV Likely pathogenic 812999 rs1596489887 GRCh37: 16:8906908-8906908
GRCh38: 16:8813051-8813051
34 INS-IGF2 , INS NM_000207.3(INS):c.174del (p.Glu59fs) Deletion Likely pathogenic 916729 GRCh37: 11:2182028-2182028
GRCh38: 11:2160798-2160798
35 HNF1A NM_000545.8(HNF1A):c.56C>T (p.Ser19Leu) SNV Uncertain significance 918071 GRCh37: 12:121416627-121416627
GRCh38: 12:120978824-120978824
36 ARMC9 NM_001352754.2(ARMC9):c.636G>C (p.Gln212His) SNV Uncertain significance 739322 rs201590882 GRCh37: 2:232099950-232099950
GRCh38: 2:231235237-231235237
37 KLF11 NM_003597.5(KLF11):c.1077G>A (p.Met359Ile) SNV Uncertain significance 330636 rs146486664 GRCh37: 2:10188541-10188541
GRCh38: 2:10048414-10048414
38 ABCC8 NM_000352.6(ABCC8):c.1562G>A (p.Arg521Gln) SNV Uncertain significance 157683 rs368114790 GRCh37: 11:17464335-17464335
GRCh38: 11:17442788-17442788
39 KCNJ11 NM_000525.4(KCNJ11):c.463G>A SNV Uncertain significance 158675 rs587783668 GRCh37: 11:17409176-17409176
GRCh38: 11:17387629-17387629
40 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain significance 128688 rs587780309 GRCh37: 9:135946855-135946855
GRCh38: 9:133071468-133071468
41 WFS1 NM_006005.3(WFS1):c.2082G>C (p.Glu694Asp) SNV Uncertain significance 918068 GRCh37: 4:6303604-6303604
GRCh38: 4:6301877-6301877

Copy number variations for Diabetes Mellitus from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 110220 17 3154257 3410803 Deletion HNF1B Diabetes mellitus
2 110369 17 31923035 33323544 Deletion HNF1B Diabetes mellitus
3 110541 17 33120546 33179209 Deletion HNF1B Diabetes mellitus
4 203632 1 158846514 158883705 Rearrangement SLAMF1 Diabetes mellitus
5 225144 7 43300000 45400000 Gain or loss GCK Diabetes mellitus
Sources

Expression for Diabetes Mellitus

About this section
Search GEO for disease gene expression data for Diabetes Mellitus.
Sources

Pathways for Diabetes Mellitus

About this section

Pathways related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.59 MIR99A MIR375 MIR30E MIR17 MIR155 MIR145
2
Regulation of beta-cell development 65
Show member pathways
 11.5 RFX6 HNF1A GCK
3
Type II diabetes mellitus 1 36
Show member pathways
 11.42 KCNJ11 HNF1A GCK
4
Parkinsons Disease Pathway 1
11.18 MIR375 MIR30E MIR17 MIR132
5
FOXA2 and FOXA3 transcription factor networks 1
10.98 KCNJ11 HNF1A GCK
Sources

GO Terms for Diabetes Mellitus

About this section

Cellular components related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 SPINK1 MIR99A MIR375 MIR30E MIR197 MIR17

Biological processes related to Diabetes Mellitus according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.8 MIR17 MIR155 MIR140 MIR132 CDKN2B-AS1
2 cellular response to hypoxia GO:0071456 9.71 MIR17 MIR155 MIR140
3 negative regulation of interleukin-6 production GO:0032715 9.63 MIR155 MIR140 MIR132
4 glucose homeostasis GO:0042593 9.56 WFS1 RFX6 HNF1A GCK
5 negative regulation of sprouting angiogenesis GO:1903671 9.54 MIR375 MIR30E MIR17
6 positive regulation of macrophage activation GO:0043032 9.52 MIR155 MIR145
7 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.51 MIR17 MIR155
8 negative regulation of vascular endothelial growth factor production GO:1904046 9.5 MIR17 MIR140 MIR134
9 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.49 MIR17 MIR155
10 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.48 MIR17 MIR155
11 regulation of insulin secretion GO:0050796 9.46 RFX6 KCNJ11 GCK CELA2A
12 type B pancreatic cell differentiation GO:0003309 9.43 RFX6 MEN1
13 gene silencing by miRNA GO:0035195 9.36 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155
14 miRNA mediated inhibition of translation GO:0035278 9.35 MIR17 MIR155 MIR145 MIR134 MIR132

Molecular functions related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
2 RNA polymerase II complex binding GO:0000993 9.13 MIR375 MIR145 MIR140
Sources

Sources for Diabetes Mellitus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....